Ginkgo Bioworks Adds Ultra-High-Throughput Screening Platform Via FGen Acquisition

Ginkgo Bioworks Holdings Inc DNA has agreed to acquire FGen AG, a Swiss company specializing in strain development and optimization. 

  • Under the transaction terms, FGen will receive an upfront payment and additional contingent consideration.
  • Specific details were not disclosed.
  • FGen has developed an ultra-high-throughput (uHT) screening platform built on nanoliter reactor technology. 
  • Ginkgo believes that FGen's technology will significantly enhance its cell screening capabilities.
  • Read Next: Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock.
  • Post-closing, Ginkgo expects that the integration of FGen's platform can significantly increase the capacity of Ginkgo's Design-Build-Test-Learn strain development engine.
  • FGen's platform is highly flexible across organisms, pathways, and target products. The platform can be deployed to screen for both intracellular and secreted target products and small molecules & proteins. 
  • It can also accommodate diverse organisms, including bacteria, yeast, filamentous species, and mammalian cells.
  • Price Action: DNA shares are down 2.93% at $2.96 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: M&ANewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!